Below are the most recent publications written about "Dengue Vaccines" by people in Profiles.
-
Adams LE, Hitchings MDT, Medina FA, Rodriguez DM, S?nchez-Gonz?lez L, Moore H, Whitehead SS, Mu?oz-Jord?n JL, Rivera-Amill V, Paz-Bailey G. Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation. Am J Trop Med Hyg. 2023 08 02; 109(2):413-419.
-
Rodriguez DM, Major CG, S?nchez-Gonz?lez L, Jones E, Delorey MJ, Alonso C, Rivera-Amill V, Paz-Bailey G, Adams LE. Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico. Vaccine. 2023 06 01; 41(24):3627-3635.
-
Chen RE, Smith BK, Errico JM, Gordon DN, Winkler ES, VanBlargan LA, Desai C, Handley SA, Dowd KA, Amaro-Carambot E, Cardosa MJ, Sariol CA, Kallas EG, S?kaly RP, Vasilakis N, Fremont DH, Whitehead SS, Pierson TC, Diamond MS. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021 11 10; 29(11):1634-1648.e5.
-
Diaz C, Koren M, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Febo I, Vaughn DW, Wilson TM, Paris RM, Schmidt AC, Thomas SJ. Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study. Am J Trop Med Hyg. 2020 05; 102(5):951-954.
-
Stauft CB, Song Y, Gorbatsevych O, Pantoja P, Rodriguez IV, Futcher B, Sariol CA, Wimmer E. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2. Virology. 2019 11; 537:237-245.
-
Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE, Wang WK. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. J Virol. 2018 12 01; 92(23).
-
Diaz C, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Toussaint JF, Febo I, Innis BL, Thomas SJ, Schmidt AC. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico. Am J Trop Med Hyg. 2018 05; 98(5):1435-1443.
-
Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016 May 15; 213(10):1562-72.
-
Pang X, Guo Y, Zhou Y, Fu W, Gu X. Highly efficient production of a dengue pseudoinfectious virus. Vaccine. 2014 Jun 24; 32(30):3854-60.
-
White LJ, Sariol CA, Mattocks MD, Wahala M P B W, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI, de Silva A, Johnston RE. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol. 2013 Mar; 87(6):3409-24.